Frequency of actionable Exomic secondary findings in 160 Colombian patients: Impact in the healthcare system

Gene. 2022 Sep 5:838:146699. doi: 10.1016/j.gene.2022.146699. Epub 2022 Jul 6.

Abstract

Introduction: By 2021, the American College of Medical Genetics and Genomics (ACMG) published the last version of their secondary findings (SF) reporting recommendations for cases in which a person receives a genetic test.

Objective: To determine in a sample of the Colombian population the prevalence of SF for the 59 genes on the ACMG SF v2.0 list associated with 27 genetic diseases.

Materials and methods: An analytical cross-sectional study was developed by examining the sequences of 160 exomes. Based on the ACMG guidelines, a variant classification algorithm was designed to filter and select reportable SF.

Results: Eleven pathogenic variants were identified in 13/160 (8.13%) patients in genes APOB, BRCA2, CACNA1S, COL3A1, LDLR, MYBPC3, PCSK9, PKP2, PMS2 and RYR2. No association was found between the sociodemographic variables and the SF to report (P > 0,05).

Conclusion: We reported the first approach of actionable pathogenic variants spectrum in the Colombian population. Given the frequency found in this study and the clinical impact of genomic variants on health, it is essential to actively search for SF having the opportunity to receive genetic counselling, prevention and clinical management.

Keywords: Genetic counseling; Genetic profile; Genetic screening; Human genetics; Incidental findings; Penetrance; Prevalence; Whole Exome Sequencing.

MeSH terms

  • Colombia / epidemiology
  • Cross-Sectional Studies
  • Delivery of Health Care
  • Genetic Testing*
  • Genetic Variation
  • Humans
  • Proprotein Convertase 9* / genetics
  • United States

Substances

  • PCSK9 protein, human
  • Proprotein Convertase 9